Business Wire

NV-ISACA

15.10.2018 15:37:05 CEST | Business Wire | Press release

Share
9 in 10 Enterprises Report Gaps Between the Cybersecurity Culture They Have and the One They Want

With cybersecurity threats continuing to escalate worldwide, the ISACA/CMMI Institute Cybersecurity Culture Report found that just 5 percent of employees think their organization’s cybersecurity culture is as advanced as it needs to be to protect their business from internal and external threats. More than 4,800 business and technology professionals shared their insights in the global research study, conducted via online polling in June 2018. Results were released today at ISACA’s CSX North America cybersecurity conference in Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005149/en/

Cybersecurity culture is a workplace culture in which security awareness and behaviors are integrated into everyone’s daily operations, as well as an executive leadership priority. In a threat-ripe environment, an effective cybersecurity culture can help employees understand their roles and responsibilities in keeping their organizations safe and customer data secure. However, just 34 percent of respondents say they understand their role in their organizations’ cyber culture.

Companies must take an all-hands-on-deck approach to counter cyberattack threats, the report summarizes.

“Enlisting the entire workforce to mitigate an enterprise’s cyber risk is an emerging practice,” says Doug Grindstaff II, SVP of Cybersecurity Solutions at CMMI Institute . “We are hearing a lot of feedback about how organizations can move the needle on employee involvement. It’s challenging, but organizations are rightly concerned by the growing sophistication of cyberattacks.”

Widespread employee involvement correlates strongly with the minority of organizations that have achieved strong satisfaction with their cybersecurity culture. Nine in ten employees (92 percent) at these organizations say that their C-level executives share an excellent understanding of the underlying issues, which may be why they loop-in their employees so well; 84 percent of employees at these organizations say they understand their role in cybersecurity.

Other critical findings include:

  • Many organizations lack the first—and all-important—step toward a cybersecurity culture: 42 percent of organizations do not have an outlined cybersecurity culture management plan or policy.
  • Aligning the entire workforce with the organization’s cybersecurity policies requires significant capital: Organizations that report a significant gap between their current and desired cybersecurity culture are spending just 19 percent of their annual cybersecurity budget on training and tools; organizations that believe their cybersecurity culture is where it is supposed to be are spending more than twice as much (43 percent).

“A key motivator for organizations delaying investing in their cybersecurity cultures is a lack of awareness about the attempted threats and ongoing risks, as well as a lack of awareness about the assets at risk to cybersecurity threats,” said Rob Clyde, NACD Board Leadership Fellow and ISACA Board Chair. “However, individuals tend to underestimate the potential damage and overestimate technology’s ability to limit such incidents. Doing so puts their organizations at serious risk.”

To view the research, visit www.isaca.org/cybersecurity-culture-study .

About ISACA

Nearing its 50th year, ISACA ® (isaca.org ) is a global association helping individuals and enterprises achieve the positive potential of technology. ISACA equips professionals with the knowledge, credentials, education and community to advance their careers and transform their organizations.

Twitter: www.twitter.com/ISACANews

About CMMI ® Institute

A subsidiary of ISACA Enterprises, CMMI Institute (cmmiinstitute.com ) is the global leader in the advancement of best practices in people, process and technology. The Institute provides the tools and support for organizations to benchmark their capabilities and maturity by comparing their operations to best practices and identifying performance gaps.

Twitter: https://twitter.com/CMMI_Institute

Contact:

ISACA Emily Van Camp, +1.847.385.7223 evcamp@isaca.org or Kristen Kessinger, +1.847.660.5512 kkessinger@isaca.org

Link:

ClickThru

Social Media:

https://www.facebook.com/ISACAHQ

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye